Transcripta Bio

Executive Summary

Transcripta Bio is a San Diego-based biotechnology company that combines artificial intelligence with high-throughput transcriptomic screening to accelerate drug discovery. Its proprietary platform profiles how thousands of molecules affect gene expression across the entire genome, generating large-scale datasets that train AI models to predict biological responses to novel compounds. By integrating experimental data with machine learning, the company aims to rapidly generate and validate therapeutic hypotheses for a wide range of human diseases. Founded in 2018, Transcripta Bio operates at the intersection of AI and functional genomics, offering a data-driven approach that could reduce the time and cost of identifying new drug candidates compared to traditional methods. While Transcripta Bio remains in a relatively early stage, its platform holds promise for transforming early-stage drug discovery, particularly in complex diseases where transcriptomic signatures can reveal novel mechanisms. The company has not yet publicly disclosed pipeline assets or clinical programs, and its funding history is unknown, suggesting it may be operating in stealth mode or relying on private investment. Key catalysts to watch include the publication of validation studies demonstrating the platform's predictive accuracy, potential pharma partnerships leveraging its screening capabilities, and a possible Series A or B financing round to scale operations. If successful, Transcripta Bio could become a valuable partner for biopharma seeking to de-risk targets and identify new biology through unbiased transcriptomic profiling.

Upcoming Catalysts (preview)

• Q3 2026Publication of platform validation data in peer-reviewed journal60% success
• Q1 2027Partnership with a major pharmaceutical company for target discovery50% success
• Q4 2026Series A or B funding round led by prominent life science VC70% success